龙牡品牌怎么样 申请店铺

我要投票 龙牡在钙片行业中的票数:186 更新时间:2025-04-03
龙牡是哪个国家的品牌?「龙牡」是武汉健民药业集团股份有限公司旗下著名品牌。该品牌发源于湖北,由创始人刘勤强在2002期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力龙牡品牌出海!通过在本页面挂载龙牡品牌的产品链接和联系邮箱,可以提高龙牡产品曝光!跨境电商爆单神器,目前只要100元/年哦~

龙牡怎么样

龙牡壮骨颗粒是武汉健民集团旗下一个有着近20年辉煌历史、创造了中国医药界长盛不衰奇迹的知名品牌,整整抚育了中国两代儿童的健康成长。

龙牡壮骨颗粒的的主要药材(如茯苓、麦冬等)都直接选用武汉健民集团专门建设的GAP药材种植基地的原料,药材天然地道。生产过程中的每个环节、每道工序都有严格的质控标准,做到了“不合格的原料不进厂,不合格的半成品不转到下道工序,不合格的产品不出厂”。

“龙牡”的面世和畅销,创造了令人惊叹的市场业绩和品牌价值,也使得武汉健民——一个有着悠久历史、而却依然年轻的企业焕发出勃勃的生机,从此享誉长城内外,大江南北。

“龙牡”,曾经独领儿童补钙产品市场的风骚。而如今,它却受到了来自其它同类竞品的强力竞争和挑战,面临着市场份额被不断蚕食和瓜分的严峻局面。抚育了中国整整二代人的茁壮成长。

1985年在武汉市儿童医院出生,填补了我国以中药为主体,防治小儿佝偻病的空白;

1990年被收载入湖北省药品标准;

1992年被列为国家唯一的补钙一级中药保护品种;

1993年被中国儿童保护中心推荐为最佳小儿补钙、促进钙质吸收药品;

1994年被全国佝偻病防治协作组列为首推中成药;

1995年被收载入卫生部药品标准;

1999年被列为国家基本药物;

2000年被中国药典2000版收载;

2002年被列为国家处方药与非处方药(OTC)双跨品种;

同年,被《中医儿科学》(新世纪全国高等中医院校规划教材)收载。

武汉健民为中国医药工业50强企业,集团股份有限公司是国家重点高新技术企业、全国中成药小儿用药生产基地、全国重点中药企业。集团的前身是中国最古老的四大中药名店之一的叶开泰药店,距今已有近四个世纪的历史,现拥有十余个子公司,集生产、科研、经贸于一体,年生产能力近十亿元。

改革开放以来,集团公司以振兴民族医药为己任,积极推进企业改革,不断探索新的管理体制和运行机制,大力提高企业创新能力,促进了公司的全面发展,企业获得了比以往任何时候都好的社会效益和经济效益,创造了国有企业稳健经营的奇迹,综合实力跻身于全国企业500强和行业50强。近几年,集团大力实施科技兴业战略,确立了坚持以中药研发、生产和销售为主业,重点开发市场急需的小儿用药,老年用药和重大疑难病症用药,构建以中药现代化、产业化为基础,以高新技术药品为支撑的科技先导型医药集团。

目前,健民集团已成功地研制和开发出以龙牡壮骨颗粒、健民咽喉片、健脾生血颗粒、便通胶囊、慢肝宁胶囊为代表的系列产品,形成了集团蔚为壮观的"名牌林",产品行销全国,远销东南亚及欧美国家和地区。集团在近些年中相继荣获"全国质量效益型先进企业"、"全国中药行业优秀企业"、"全国五一劳动奖状"等称号,被誉为"搞好搞活国有企业的一面旗帜","健民"商标亦荣获"驰名保护"称号。一个以中药产业为基础,以高新科技为特征的健民集团必将在新的世纪里创更辉煌的业绩,谱写出振兴国药的优美乐章。

Longmu Zhuanggu Granule is a well-known brand under Wuhan Jianmin group, which has a glorious history of nearly 20 years and has created a long-lasting miracle in the field of Chinese medicine. It has nurtured the healthy growth of two generations of children in China. The main medicinal materials of Longmu Zhuanggu granules (such as Poria cocos, Ophiopogon japonicus, etc.) are directly selected from the gap medicinal materials planting base specially built by Wuhan Jianmin group, which are natural and authentic. There are strict quality control standards for each link and process in the production process, so that "unqualified raw materials are not allowed to enter the factory, unqualified semi-finished products are not transferred to the next process, and unqualified products are not allowed to leave the factory". The appearance and best-selling of "Longmu" has created amazing market performance and brand value, and also made Wuhan Jianmin, an enterprise with a long history but still young, full of vitality. Since then, it has been famous inside and outside the Great Wall, North and south of the river. "Longmu" once led the market of children's calcium supplement products. But now, it is faced with strong competition and challenge from other competitors, and the market share is constantly eroded and divided. He nurtured two generations of Chinese people. Born in Wuhan children's Hospital in 1985, it has filled in the blank of prevention and treatment of rickets in China with traditional Chinese medicine as the main body; in 1990, it was included in the drug standard of Hubei Province; in 1992, it was listed as the only one level of protection of traditional Chinese medicine for calcium supplement; in 1993, it was recommended as the best drug for children's calcium supplement and calcium absorption by China children's protection center; in 1994, it was recommended by the National Coordination Group for prevention and treatment of rickets It was listed as the first Chinese patent medicine; in 1995, it was listed in the drug standard of the Ministry of health; in 1999, it was listed as the national basic drug; in 2000, it was listed in the 2000 edition of the Chinese Pharmacopoeia; in 2002, it was listed as the national prescription medicine and over-the-counter medicine (OTC) double cross varieties; in the same year, it was listed in the pediatrics of traditional Chinese medicine (the textbook for the planning of the national higher education of traditional Chinese medicine in the new era). Wuhan Jianmin is one of the top 50 enterprises in China's pharmaceutical industry. The Group Co., Ltd. is a national key high-tech enterprise, a national production base of Chinese patent medicine for children and a national key Chinese medicine enterprise. The group's predecessor is Ye Kaitai drugstore, one of the four oldest famous traditional Chinese medicine stores in China. It has a history of nearly four centuries. Now it has more than ten subsidiaries, integrating production, scientific research and economic and trade, with an annual production capacity of nearly one billion yuan. Since the reform and opening up, the group company has taken the revitalization of national medicine as its own duty, actively promoted the enterprise reform, constantly explored new management system and operation mechanism, vigorously improved the innovation ability of the enterprise, promoted the overall development of the company, obtained better social and economic benefits than ever before, created a miracle of steady operation of state-owned enterprises, and its comprehensive strength ranks among Top 500 enterprises and top 50 industries in China. In recent years, the group has vigorously implemented the strategy of developing industry through science and technology, established a science and technology leading pharmaceutical group based on the modernization and industrialization of traditional Chinese medicine, supported by high-tech drugs, which adheres to the R & D, production and sales of traditional Chinese medicine as the main business, focuses on the development of children's drugs, elderly drugs and drugs for major and difficult diseases urgently needed in the market. At present, Jianmin group has successfully developed and developed a series of products represented by Longmu Zhuanggu granules, Jianmin Yanhou tablets, Jianpi Shengxue granules, Bentong capsules and manganning capsules, forming a spectacular "famous brand forest" of the group, which is sold all over the country and exported to Southeast Asia, European and American countries and regions. In recent years, the group has been awarded the titles of "national advanced quality and benefit enterprise", "national excellent enterprise in traditional Chinese medicine industry", "National May 1st Labor Award", etc., known as "a banner for invigorating state-owned enterprises", and the trademark of "invigorating the people" has also been awarded the title of "well-known protection". A Jianmin group based on traditional Chinese medicine industry and characterized by high and new technology is bound to make more brilliant achievements in the new century and compose a beautiful movement to revitalize traditional Chinese medicine.

本文链接: https://brand.waitui.com/ef134bbd9.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

稀土永磁板块短线拉升,九菱科技涨超10%

36氪获悉,截至发稿,稀土永磁板块短线拉升,九菱科技涨超10%,英思特、正海磁材、金力永磁、银河磁体、西磁科技等跟涨。

2小时前

毕马威:人形机器人去年融资规模超72亿元,近年年均复合增长率35.6%

毕马威发布报告称,人形机器人作为具身智能的代表形态之一,市场前景广阔。2024年全球人形机器人市场规模达到20.3亿美元,预计到2029年将达到132.5亿美元,年均复合增长率约45.5%。“投融资方面,中国具身智能的投融资市场正呈现热潮调整、恢复向好的趋势。2024年具身智能融资共182笔,金额为140.5亿元,出现复苏现象。”毕马威指出,“作为具身智能子赛道,人形机器人因丰富的应用场景与技术发展潜力,其融资表现逆势增长,融资规模从2020年的15.8亿元升至去年的72.3亿元,年均复合增长率为35.6%。”(澎湃)

2小时前

3月份部分热点城市房地产市场活跃度大幅提升

据中国房地产业协会,得益于供给放量、房企营销力度增加,以及政策效应持续释放的多重因素推动下,3月份部分热点城市房地产市场活跃度大幅提升。回暖迹象明显。特别是一线城市及部分核心二线城市,新房和二手房成交量环比显著增长,迎来一波局部“小阳春”行情。克而瑞数据显示,2025年3月份30个监测城市新房成交规模为1230万平方米,环比增长79%,同比上升4%。春节后季节性需求释放、政策宽松及房企促销推动成交回升,一季度30城累计成交2810万平方米,同比上涨7%。(证券时报)

2小时前

小鹏汽车在成都成立销售服务新公司,注册资本500万

36氪获悉,天眼查App显示,近日,成都悦鹏汽车销售服务有限公司成立,法定代表人为韩键,注册资本500万人民币,经营范围包括新能源汽车整车销售、新能源汽车电附件销售、机动车充电销售、电池零配件销售、汽车零配件批发、小微型客车租赁经营服务等,由成都小鹏汽车销售服务有限公司全资持股。

2小时前

国家绿色发展基金入股宜宾高投产业发展公司

36氪获悉,天眼查App显示,近日,宜宾高投产业发展有限公司发生工商变更,新增国家绿色发展基金股份有限公司为股东,同时注册资本由10亿人民币增至约13.8亿人民币。该公司成立于2023年2月,法定代表人为何流,经营范围包括自有资金投资的资产管理服务、企业管理、融资咨询服务等,现由宜宾市高新投资集团有限公司及上述新增股东共同持股。

2小时前

本页详细列出关于盖中盖的品牌信息,含品牌所属公司介绍,盖中盖所处行业的品牌地位及优势。
咨询